# US 2021/0065846 A1 · Assessment of Polygenic Trait Risk via Trait Components and Applications Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0065846 A1
- Document ID: US20210065846A1
- Status: Published application
- Kind: A1
- Application number: 17/005,241
- Filed: 2020-08-27
- Published: 2021-03-04
- Earliest claimed: 2019-08-27
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Manuel A. Rivas; Matthew Woodward Aguirre
- Web page: https://patentgrep.com/patent/US20210065846A1

## CPC

- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Methods to determine an individual's propensity or risk for a trait and applications thereof are described. Generally, systems and methods utilize genetic data acquired from an individual to determine their propensity or risk for a set of components that contribute to a trait. Propensity or risk of a trait is determined by assessing propensity or risk for each component of a set of components and the weighted contribution of each component to the trait.

## Claims

### Claim 1

A method to determine an individual's risk for a medical disorder for treatment or further diagnostic assessment, comprising:
obtaining or having obtained genetic sequence data comprising variants of an individual;
for a medical disorder, determining or having determined a component polygenic risk score for each component of a set of components;
utilizing the set of component polygenic risk scores, determining or having determined a comprehensive polygenic score for the medical disorder, wherein the comprehensive polygenic score indicates the individual is likely to have or to develop the medical disorder;
based on the comprehensive polygenic score, performing a treatment on the individual for the medical disorder or performing a diagnostic on the individual to further assess the medical disorder.

### Claim 2 (depends on 1)

The method according to claim 1 further comprising:
determining or having determined the contribution of a number of components of the set of components, wherein the contribution of at least one component indicates that the at least one component is a factor involved in manifestation of the polygenic disorder;
wherein the performing the treatment or the performing the diagnostic is directed towards the at least one component based on the contribution of the at least one component.

### Claim 3 (depends on 2)

The method of claim 2, wherein the components that assessed for contribution have the same sign as the comprehensive polygenic risk score.

### Claim 4 (depends on 1)

The method according to claim 1 further comprising:
obtaining or having obtained a biopsy from the individual;
extracting or having extracted DNA from the biopsy;
sequencing or having sequenced the extracted DNA to yield the genetic sequence data.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the variants comprise at least one of: single nucleotide variants, insertions, deletions, copy number variants, or HLA alleles.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the medical disorder is one of:
Alzheimer's disease, arthritis, asthma, coronary artery disease, Crohn's disease, dementia, diabetes, heart disease, heart failure, cholesterol imbalance, hypertension, hypothyroidism, irritable bowel syndrome, obesity, Parkinson's disease, psoriasis, sleep apnea, or stroke.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the number of components in the set of components is an integer between 50 and 500.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the number of components is

### Claim 9 (depends on 1)

The method according to claim 1, wherein the set of components is determined by decomposing the genetic associations of the medical disorder by determining associations between the variants and underlying or related traits.

### Claim 10 (depends on 9)

The method according to claim 9, wherein a truncated singular value decomposition is utilized to identify the set of components.

### Claim 11 (depends on 1)

The method according to claim 1, wherein each component polygenic risk score is computed by assuming variants make additive contributions.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the comprehensive polygenic score is determined by aggregating each component polygenic risk score of the set of components.

### Claim 13 (depends on 12)

The method according to claim 12, where each component polygenic risk score of the set of components is computed using genome wide association beta or z-statistics.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the comprehensive polygenic risk score is adjusted by age, sex, genetic principal components, or any combination thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the adjustment is performed by fitting a multiple regression model with polygenic risk scores and covariates in a validation population.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the comprehensive polygenic risk score is above a threshold.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the threshold is determined empirically to capture a certain percentage of individual having the medical disorder in a population.

### Claim 18

A method to determine an individual's propensity for a polygenic trait, comprising:
obtaining or having obtained genetic sequence data comprising variants of an individual;
for a polygenic trait, determining or having determined a component polygenic risk score for each component of a set of components;
utilizing the set of component polygenic risk scores, determining or having determined a comprehensive polygenic score for the trait, wherein the comprehensive polygenic score indicates the individual is likely to have or to develop the trait.

### Claim 19 (depends on 18)

The method as in claim 18, wherein the set of components is determined by decomposing the genetic associations of the trait by determining associations between the variants and underlying or related traits.

### Claim 20 (depends on 19)

The method according to claim 19, wherein a truncated singular value decomposition is utilized to identify the set of components.

### Claim at position 21


